[Use of metformin in patients with type 2 diabetes and acute myocardial infarction: safety and impact on glycemic control].

BACKGROUND: Myocardial infarction (MI) in patients with diabetes type 2 (T2DM) occurs 1.5-3.0 times higher than in general population. Metformin is contraindicated for patients with T2DM and acute coronary syndrome due to the risk of developing lactic acidosis. Using metformin more than 48 hours of MI is a topical question, which will help to improve patient's safety. AIM: To evaluate the safety and quality of glycemic control using metformin in patients with T2DM during inpatient treatment for MIMATERIALS AND METHODS: The study included 161 patients with T2DM, who were hospitalized consecutively with acute MI with ST-elevation and underwent percutaneous coronary intervention (PCI). Average time of metformin initiation was 5th day from admission. Creatinine was assessed at admission and 48 hours after PCI. The acid-base balance and lactate were assessed at admission and on the 3rd day after the start of using metformin. Criteria for the effectiveness of glycemic control was the proportion of glycemic measurements in target range of 6.1-10.0 mmol/l during hospitalization ("hospital time in range", hTIR). hTIR >55% was considered to be a critical level. The long-term outcome was estimated at 365 days after hospitalization. RESULTS: Metformin was prescribed to 99 patients (61%) ("M+"group) during the hospitalization, 62 patients were in "M-"group. Use of metformin was accompanied with better glycemic control in the «M+¼ group compared to the «M-¼: mean glycemia 9.3 ± 1.6 vs 10.3 ± 2.3 mmol/l (p=0,002), SD 2.87 ± 1.1 vs 3.26 ± 1.8 (p=0,049), hTIR 60 ± 18% vs 48 ± 23% (p<0,001). There were clinically insignificant changes in acid-base balance on the 3rd day from the start of metformin use in the "M+" group, the lactate level did not increase. Use of metformin before to hospitalization with MI was not associated with an increased risk of developing acute kidney injury (AKI): RR 0.85 (0.37-1.96), p=0,691. CONCLUSION: Use of metformin in patients with T2DM and acute MI is associated with better glycemic control. Carrying out angiography in patients, treated with metformin before the hospitalization, is not accompanied by an increased risk of developing AKI. Appointment of metformin in 3-7 days after angiography does not lead to an increase level of lactate and significant deviations in acid-base balance.

[Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders].

BACKGROUND: There is a lack of data on the features of dysglycemia in hospitalized patients with COVID-19 and concomitant diabetes mellitus (DM) confirmed by continuous glucose monitoring (CGM). AIM: to study the glycemic profile in hospitalized patients with COVID-19 and type 2 diabetes mellitus by continuous glucose monitoring and the role of steroid therapy in dysglycemiadevelopment. MATERIALS AND METHODS: We examined 21 patients with COVID-19 and DM 2 and 21 patients with DM 2 without COVID-19 (control group) using a professional 4-7-day CGM. We also compared two subgroups of patients with COVID-19 and DM 2: 1) patients received systemic glucocorticosteroids (GCS) during CGM and 2) patients in whomCGMwas performed after discontinuation of GCS. RESULTS: Compared with controls, patients with COVID-19 and DM2 had lesser values of glycemic «time in range¼ (32.7 ± 20.40 vs 48.0 ± 15.60%, p = 0.026) andhigher parameters of mean glycemia (p <0.05) but similar proportion of patients with episodes of hypoglycemia (33.3% vs 38.1%, p = 0.75). Patients who received dexamethasone during CGM were characterized by higher hyperglycemia and the absence of episodes of hypoglycemia. In patients who hadCGM after dexamethasone discontinuation, hyperglycemia was less pronounced, but 60% of them had episodes of hypoglycemia, often nocturnal, clinically significant and not detected by routine methods. CONCLUSION: Patients with COVID-19 and DM 2had severe and persistent hyperglycemia but a third of them hadalso episodes of hypoglycemia. During therapy with dexamethasone, they had the most pronounced hyperglycemia without episodes of hypoglycemia. In patients who underwent CGM after discontinuation of dexamethasone, hyperglycemia was less pronounced but 60% of them have episodes of hypoglycemia, often nocturnal, clinically significant and not diagnosed by routine methods. It would be advisable to recommend at least a 5-6-fold study of the blood glucose level (with its obligatory assessment at night) even for stable patients with COVID-19 and DM 2after the end of GCS treatment.

COVID-19 in Patients with Diabetes: Clinical Course, Metabolic Status, Inflammation, and Coagulation Disorder.

The aim of the investigation was to study the clinical course of COVID-19 in the presence of diabetes mellitus (DM) and elucidate possible mechanisms of their mutual aggravation. Materials and Methods: The study included 64 patients with COVID-19; of them, 32 were with DM (main group) and 32 were DM-free (control group). The groups were formed according to the "case-control" principle. During hospitalization, the dynamics of clinical, glycemic, and coagulation parameters, markers of systemic inflammation, as well as kidney and liver functions were monitored and compared. Results: Among patients with DM, the course of viral pneumonia was more severe, as evidenced by a 2.2-fold higher number of people with extensive (>50%) lung damage (p=0.05), an increased risk of death according to the CURB-65 algorithm (1.3-fold, p=0.043), and a longer duration of insufficient blood oxygen saturation (p=0.0004). With the combination of COVID-19 and DM, hyperglycemia is persistent, without pronounced variability (MAGE - 1.5±0.6 mmol/L), the levels of C-reactive protein (p=0.028), creatinine (p=0.035), and fibrinogen (p=0.013) are higher, manifestations of hypercoagulability persist longer, including slower normalization of antithrombin III (p=0.012), fibrinogen (p=0.037), and D-dimer (p=0.035). Conclusion: The course of COVID-19 in patients with DM is associated with a high severity and extension of pneumonia, persistent decrease in oxygen supply, high hyperglycemia, accelerated renal dysfunction, systemic inflammation, and hypercoagulability.

Diagnostic Capabilities of Islet Autoantibodies in Children with New-Onset Type 1 Diabetes Mellitus and Healthy Siblings.

The aim of the study is to determine the diagnostic utility of several islet autoantibodies and their combinations in order to identify individuals susceptible to type 1 diabetes mellitus (T1DM) among healthy siblings in the pediatric population within the scope of the development of a screening program. MATERIALS AND METHODS: A total of 424 children were evaluated, 260 children with new-onset T1DM and 164 healthy children with brothers and/or sisters with T1DM.Blood tests for a complex of autoantibodies to insulin (IAA), tyrosine phosphatase (IA-2A), zinc transporter 8 (ZnT8A), pancreatic ß-cells (ICA), and glutamate decarboxylase (GADA) were conducted in all the subjects with the enzyme immunoassay method. RESULTS: It was found that the diagnostic utility of individual autoantibodies is not equal and varies with age. The optimal age groups for the immunological control of the risks of developing type 1 diabetes in healthy siblings were determined. The highest risks were noted with the combination of GADA, ZnT8A, and IA-2A. CONCLUSION: Islet autoantibodies may serve as prognostic markers of the risk of developing type 1 diabetes in healthy siblings.

Effect of Type 2 Diabetes Mellitus on Five-Year Survival of Patients Hospitalized Because of Acute Decompensated Heart Failure.

OBJECTIVE: To assess the impact of type 2 diabetes mellitus (T2DM) on prognosis of patients hospitalized because of acute decompensated heart failure (ADHF). MATERIALS AND METHODS: We analyzed data of the hospital register of ADHF which comprised information on 735 patients (254 [35%] with T2DM) consecutively admitted in 2010-2011. Median follow-up was 1790 days. RESULTS: The presence of T2DM was associated with increased risk of death: during the index hospitalization due to ADHF (hazard ratio [HR] 1.7, 95% confidence interval [CI] 1.0-2.8), within 18 months (HR 1.4, 95% CI 1.0-1.8), and within 5 years (HR 1.3, 95% CI 1.0-1.5). CONCLUSIONS: T2DM is common among acute decompensated heart failure patients (up to 35% of cases). T2DM is an independent risk factor of death during the index hospitalization and over the next 18 months and 5 years.

[Effect of Type 2 Diabetes Mellitus on Five­Year Survival of Patients Hospitalized Because of Acute Decompensated Heart Failure].

OBJECTIVE: To assess the impact of type 2 diabetes mellitus (T2DM) on prognosis of patients hospitalized because of acute decompensated heart failure (ADHF). MATERIALS AND METHODS: We analyzed data of the hospital register of ADHF which comprised information on 735 patients (254 [35%] with T2DM) consecutively admitted in 2010-2011. Median follow­up was 1790 days. RESULTS: The presence of T2DM was associated with increased risk of death: during the index hospitalization due to ADHF (hazard ratio [HR] 1.7, 95% confidence interval [CI] 1.0-2.8), within 18 months (HR 1.4, 95% CI 1.0-1.8), and within 5 years (HR 1.3, 95% CI 1.0-1.5). CONCLUSIONS: T2DM is common among acute decompensated heart failure patients (up to 35% of cases). T2DM is an independent risk factor of death during the index hospitalization and over the next 18 months and 5 years.

[Variability of glycemia and ventricular rhythm disturbances in patients with chronic heart failure and type 2 diabetes mellitus].

Aim of this observational study was assessment of effect of variability of glycemia on ventricular ectopic activity in patients with chronic heart failure (CHF) and type 2 diabetes mellitus (n=80). According to study protocol 24-hour Holter ECG monitoring was carried out at baseline, and after 3 and 6 months. Measurements of blood glucose level were made at 8 points during ECG monitoring - before and in 2 hours after main meals, before bedtime and at 3 o'clock in the morning. In 20 patients continuous combined monitoring of ECG and of blood glucose level was carried out. During monitoring of ECG high grade ventricular arrhythmias were found in 42 patients (53%). Pronounced variations of blood glucose level (mean amplitude of glycemic excursion >5 mmol/L) were associated with 2.3 fold increase risk of ventricular arrhythmias (p=0.04). A conclusion was made that pronounced 24-hour variations of glucose level in blood was associated with elevation of ventricular ectopic activity. High 24-hour variability of glycemia appeared to be proarrhythmogenic factor in patients with CHF and concomitant diabetes.

[Hematological disturbances in subclinical hypothyroidism and their dynamics during substitution therapy].

The aim of the study was to estimate dynamics of hematological disturbances in autoimmune thyroiditis and subclinical hypothyroidism (SH) during substitution therapy and without it and to elucidate factors promoting successful correction. The control group included 36 women, 60 others had SH. They were matched for age, BMI, free T3 level but differed in TSH (1.8 +/- 0.81 vs 7.0 +/- 3.41 mcunits/ml, p < 0.001) and T4 (p < 0.001) levels. 53 women with SH were followed up for 1 year; 18 of them were not treated (subgroup A) while 35 were given levothyroxin (subgroup B). The following red blood parameters were measured hemoglobin (Hb), ferritin, mean erythrocyte volume, erythrocyte Hb content and concentration, blood iron (Fe) level. SH was characterized by decreased (compared with control) Hb levels (125.8 +/- 13.75 and 133.2 +/- 9.12 g/l, p = 0.005), erythrocyte volume (p = 0.022), Hb content per erythrocyte (p = 0.001), ferritin (24.6 +/- 20.56 vs 36.6 +/- 30.66 mcg/l, p = 0.02), and Fe (p = 0.001). The frequency of anemia (28.3 vs 11.1%, p = 0.039) especially microcytic anemia (p = 0.035) increased A year later women of subgroup A showed further decrease in ferritin level (p = 0.011) and increase in anemia frequency (p = 0.016): microcytic (p = 0.23) and normocytic (p = 0.015). In subgroup B, the frequency of anemia decreased (p = 0.001) while ferritin, Fe and Hb levels slightly increased (p > 0.05). The best effect of therapy and highest rise in ferritin level were documented in younger patients (p = 0.06), in the absence of obesity (p = 0.003) and at the low initial ferritin level (p < 0.001). In regression analysis, ferritin level (094 [0.89; 0.99], p = 0.035) proved the most significant predictor of therapeutic effectiveness. SH was characterized by Fe deficiency, tendency to microcytosis and anemia that progressed in the absence of therapy. Substitution therapy promotes normalization of hematological problems especially in young and non-obese patients. Sideropenic syndrome suggests potential benefits of levothyroxin therapy and may be regarded as an additional indication for its prescription.

[Intensive glycemia control in the first day of the acute cerebral blood flow disturbance in patients with diabetes mellitus type 2].

Forty-seven patients with cerebral stroke and diabetes mellitus type 2 were included in the study. To maintain the target values of glycemia on the level 7.8-10.2 mmol/l, patients of the main group received the continuous intravenous infusion of insulin and patients of the control group received frequent (every 3h) subcutaneous injections of insulin during the first 24 h after the acute cerebral blood flow disturbance. The results obtained have shown that continuous intravenous insulin infusion reduces the risk of hypoglycemia, accelerates positive neurologic dynamics, reduces terms of hospitalization and decreases mortality in patients with diabetes mellitus type 2.

[Efficacy of strict glycemic control in first 24 hours of myocardial infarction in patients with type 2 diabetes mellitus].

The study evaluated the influence of strict glycemic control during first 24 hours of myocardial infarction on 6-months mortality and systolic function of the left ventricle. Of 65 patients with type 2 diabetes mellitus and acute myocardial infarction 30 received 24-hour infusion of short acting insulin and 35 served as controls. As a result of this investigation we made a conclusion that effect of optimal metabolic control during acute period of myocardial infarction on mortality and constriction of the left ventricular was beneficial.

[Effectiveness and safety of radioiodine therapy for Graves' disease].

In 2005, in the MD PU City Hospital No. 13 of Nizhny Novgorod, a radiological department was created on the basis of a radioisotope laboratory for treating patients with Graves' disease with a radioiodine, which treats patients in the Nizhny Novgorod region and other regions of Russia. OBJECTIVE: to determine the effectiveness of radioiodine therapy in Graves disease and the dependence of the outcome on the applied 131I activities and thyrostatic therapy.

[Disturbances of cardiac rhythm and metabolic control in patients with type-2 diabetes].

Twenty four hour ECG monitoring, registration of ventricular late potentials, and measurement of glycated hemoglobin (HbA1c) were included into examination of 142 cardiological patients (101 with and 41 without type 2 diabetes). Groups of patients with and without diabetes had similar age and severity of cardiac pathology. Patients with diabetes had more prognostically and hemodynamically unfavorable arrhythmias -- paroxysmal and permanent atrial fibrillation, high grade ventricular extrasystoles (HGVE) and their combinations. Atrial fibrillation and HGVE were more often observed in diabetic patients with HbA1c <7 and >8.5%, respectively. Date of registration of ventricular late potentials in patients with diabetes mellitus (QRSTt >110 ms, LAS40 >37 ms, and RMS <23 mcV) possess high informative power not only in prognosis of HGVE but also evidences for bad control of glycemia.

[Chronic heart failure in patients with type-2 diabetes].

Combination of diabetes and chronic heart failure is a frequently occurring syndrome. We studied interrelationship between state of carbohydrate metabolism, diabetic nephropathy and level of natriuretic peptide in patients with type 2 diabetes and concomitant chronic heart failure. The study confirmed high diagnostic value of natriuretic peptide as quantitative criterion of the presence of heart failure and revealed association of decompensation of carbohydrate metabolism and presence of diabetic nephropathy with more severe heart failure and left ventricular dysfunction. Among patients with renal failure those with more severe heart failure had low values of glycosylated hemoglobin.

[Characteristics of the dynamic outpatient observation of workers at an industrial enterprise]. / Osobennosti dinamicheskogo dispansernogo nabliudeniia rabotnikov promyshlennogo predpriiatiia.

A computer-assisted staged system of a follow-up of factory workers with CHD and diabetes mellitus was developed. It included automated screening by questionnaire, ECG and biochemical screening, physical examination, investigation of the basic carbohydrate-lipid indices, more detailed examination in out- or inpatients settings using up-to-date diagnostic methods (bicycle ergometry, monitoring after Holter, etc.), identification of groups for a follow-up, and therapeutic and sanitary measures. A total of 27750 persons were investigated. The most important group was that including persons with risk factors: vegetovascular dystonia developing into CHD (6%) or essential hypertension (20%). Sanitary measures by unified methods caused a decrease in temporary disability with the economic effect of 197,000 rubles.